Table 3 The diagnostic performance of FIT at 10, 20, 30, 40, 50, 75, and 100 μg Hb/g for patients aged 18–29 years, 30–39 years, and 18–39 years.
18–29 years | ||||
Threshold, μg Hb/g | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV, % (95% CI) | NPV, % (95% CI) |
10 | 100 (29.2–100) | 86.1 (85.1–87.0) | 0.4 (0.1–1.3) | 100 (99.9–100) |
20 | 100 (29.2– 100) | 88.9 (88.0– 89.8) | 0.6 (0.1–1.6) | 100 (99.9–100) |
30 | 100 (29.2–100) | 90.3 (89.4–91.1) | 0.6 (0.1–1.9) | 100 (99.9–100) |
40 | 100 (29.2–100) | 91.3 (90.4–92.1) | 0.7 (0.1–2.1) | 100 (99.9–100) |
50 | 100 (29.2–100) | 91.8 (91.0–92.5) | 0.8 (0.2–2.2) | 100 (99.9–100) |
75 | 66.7 (9.4–99.2) | 92.8 (92.1–93.6) | 0.6 (0.1–2.1) | 100 (99.9–100) |
100 | 66.7 (9.4–99.2) | 93.4 (92.7–94.1) | 0.6 (0.1–2.3) | 100 (99.9–100) |
30–39 years | ||||
10 | 88.9 (65.3–98.6) | 88.5 (87.9–89.1) | 1.2 (0.7–1.9) | 100 (99.9–100) |
20 | 83.3 (58.6–96.4) | 91.1 (90.5–91.6) | 1.4 (0.8–2.3) | 100 (99.9–100) |
30 | 77.8 (52.4–93.6) | 92.4 (91.9–92.9) | 1.6 (0.9–2.6) | 100 (99.9–100) |
40 | 77.2 (46.5–90.3) | 93.3 (92.8–93.7) | 1.6 (0.9–2.8) | 100 (99.9–100) |
50 | 66.7 (41.0–86.7) | 93.8 (93.3–94.2) | 1.6 (0.8–2.8) | 99.9 (99.9–100) |
75 | 61.1 (35.7–82.7) | 94.8 (94.4–95.2) | 1.8 (0.9–3.1) | 99.9 (99.9–100) |
100 | 61.1 (35.7–82.7) | 95.3 (94.9–95.7) | 2.0 (1.0–3.5) | 99.9 (99.9–100) |
18– 39 years | ||||
Threshold, μg Hb/g | Sensitivity | Specificity | PPV | NPV |
10 | 90.5 (69.6–98.8) | 87.8 (87.3–88.3) | 0.9 (0.6–1.5) | 100 (99.9–100) |
20 | 85.7 (63.7–97.0) | 90.4 (90.0–90.9) | 1.1 (0.7–1.8) | 100 (99.9–100) |
30 | 81.0 (58.1–94.6) | 91.8 (91.4–92.2) | 1.2 (0.7–2.0) | 100 (99.9–100) |
40 | 76.2 (52.8–91.8) | 92.7 (92.3–93.1) | 1.3 (0.8–2.1) | 100 (99.9–100) |
50 | 71.4 (47.8–88.7) | 93.2 (92.8–93.6) | 1.3 (0.7–2.2) | 100 (99.9–100) |
75 | 61.9 (38.4–81.9) | 94.2 (93.8–94.6) | 1.3 (0.7–2.3) | 99.9 (99.9–100) |
100 | 61.9 (38.4–81.9) | 94.8 (94.4–95.1) | 1.5 (0.8–2.5) | 99.9 (99.9–100) |